The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Open accessAbstract
Microglia and macrophages accumulate at the sites of active demyelination and neurodegeneration in the multiple sclerosis brain and are thought to play a central role in the disease process. We used recently described markers to characterize the origin and functional states of microglia/macrophages in acute, relapsing and progressive multiple sclerosis. We found microglia activation in normal white matter of controls and that the degree of activation increased with age. This microglia activation was more pronounced in the normal-appearing white matter of patients in comparison to controls and increased with disease duration. In contrast to controls, the normal-appearing white matter of patients with multiple sclerosis showed a significant reduction of P2RY12, a marker expressed in homeostatic microglia in rodents, which was completely lost in active and slowly expanding lesions. Early stages of demyelination and neurodegeneration in active lesions contained microglia with a pro-inflammatory phenotype, which expressed molecules involved in phagocytosis, oxidative injury, antigen presentation and T cell co-stimulation. In later stages, the microglia and macrophages in active lesions changed to a phenotype that was intermediate between pro- and anti-inflammatory activation. In inactive lesions, the density of microglia/macrophages was significantly reduced and microglia in part converted to a P2RY12+ phenotype. Analysis of TMEM119, which is expressed on microglia but not on recruited macrophages, demonstrated that on average 45% of the macrophage-like cells in active lesions were derived from the resident microglia pool. Our study demonstrates the loss of the homeostatic microglial signature in active multiple sclerosis with restoration associated with disease inactivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, microglia in active MS lesions lack Tmem119 (Satoh et al., 2016; Zrzavy et al., 2017).”
From Activated microglia drive demyelination via CSF1R signaling (2021) · cites this paper as Zrzavy et al., 2017
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial cells within active white matter lesions are characterized by the absence of homeostatic markers such as P2RY12 and an upregulation of CXCR4, indicating a shift to a disease-associated state (31, 41, 42).”
From The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors (2025) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TMEM119 is one of the main homeostatic microglia markers that is not expressed on monocyte-derived macrophages and has been shown to be downregulated in active MS lesions and other inflammatory conditions of the brain47–49.”
From CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, the phenotype of microglia we observed in HDLS is similar to that found in an SOD1 ALS mouse model and in multiple sclerosis patients, in which the molecules associated with the homeostatic microglial phenotype (e.g., P2RY12, CSF-1R) are down-regulated and inflammatory markers are up-regulated [24, 57].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As reported previously (Zrzavy et al., 2017), P2RY12+ cells expressing TSPO were substantially reduced in active lesions (Fig. 2E–H).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Zrzavy et al., 2017
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, in contrast to the pattern of TSPO expression in rodent models, it may not be so specifically associated with pro-inflammatory microglia in multiple sclerosis (Zrzavy et al., 2017).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Zrzavy et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, most phagocytes initially present in active MS lesions are microglia, and with lesion maturation, more macrophages will infiltrate from the blood47.”
From CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis (2024) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“TMEM119 is one of the main homeostatic microglia markers that is not expressed on monocyte-derived macrophages and has been shown to be downregulated in active MS lesions and other inflammatory conditions of the brain47–49.”
From CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis (2024) · cites this paper as [47]
In the citing paper
“The loss of homeostatic microglial proteins is visible in immunofluorescence double-staining of IBA1 and TMEM119 in terminally sick mice and mock-infected healthy control brains, and shows the reciprocal regulation of both proteins in prion disease (Figure 5A) [55,73,88,89,90,91].”
From Loss of Homeostatic Microglia Signature in Prion Diseases (2022) · cites this paper as [90]
In the citing paper
“since its expression is maintained by resident human microglia in MS lesions and is not expressed by infiltrating immune cells (Zrzavy et al., 2017).”
From Complex cell-state changes revealed by single cell RNA sequencing of 76,149 microglia throughout the mouse lifespan and in the injured brain (2018) · cites this paper as Zrzavy et al., 2017
In the citing paper
“Several of these microglial genes were also observed in human microglia, including P2RY12 and TMEM119 (REFs25,33–36).”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [36]
In the citing paper
“In human MS, microglia lose the expression of the P2RY12 homeostatic microglial marker and adopt a pro-inflammatory phenotype that includes the expression of phagocytic-related markers (macrosialin (also known as CD68)), antigen presentation markers (MHC class I and II molecules and T lymphocyte activation antigen CD86) and proteins involved in the production of reactive oxygen species (cytochrome”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [36]
In the citing paper
“and appears to exhibit stable expression even in response to a variety of inflammatory conditions (9, 96).”
From The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease (2019) · cites this paper as [96]
In the citing paper
“Studies have shown that microglial migration, proliferation, and activation are involved in the onset and progression of disease in acute, relapsing, and progressive forms of MS in humans (Zrzavy et al. 2017).”
From MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis (2025) · cites this paper as Zrzavy et al. 2017
In the citing paper
“However, activation conditions are variable and microglial phenotype changes with disease progression (Zrzavy et al. 2017).”
From MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis (2025) · cites this paper as Zrzavy et al. 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543
Self-citationthe Immunological Genome Consortium, Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2419 · Cited by 1,972 · cited 1×
“…to be microglia-specific in comparison to other brain cells (Chiu et al., 2013; Hickman et al., 2013) or in comparison to peripheral myeloid cells (Gautier et al., 2012; Hickman et al., 2013; Butovsky et al., 2014) or to be involved in pro- or anti-inflammatory microglia/macrophage function such…”
BackgroundNew tools for studying microglia in the mouse and human CNS
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., Mulinyawe, S. B., Bohlen, C. J., Adil, A., Tucker, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525528113 · Cited by 1,804
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777 · cited 1×
“It has been suggested to stimulate remyelination (Butovsky et al., 2006; Miron et al., 2013) and early stages of remyelination within multiple sclerosis lesions are mainly seen in the core of active lesions (Raine et al., 1981; Prineas et al., 1993; Raine, 2017).”
A polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
Microglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Flagged first, then by citations
1 of the 68 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Babinski, 1885, Recherches sur l’anatomie pathologique de la sclerose en plaque et étude comparative des diverses variétés de la scleroses de la moelle, Arch Physiol, 5, 186
- Marburg, 1906, Die sogenannte akute multiple Sklerose, J Psychiatric Neurol, 27, 1
Cited by
Sorted by citations
Items 301–400 of 698
Miedema, A., Wijering, M. H. C., Eggen, B. J. L., & Kooistra, S. M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.583811 · Cited by 24
Brain-derived CCR5 Contributes to Neuroprotection and Brain Repair after Experimental Stroke
Ping, S.-N., Qiu, X., Kyle, M., & Zhao, L.-R. (2021) · Aging and Disease · doi:10.14336/ad.2020.0406 · Cited by 21
CNS Resident Innate Immune Cells: Guardians of CNS Homeostasis
Muzio, L., & Perego, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094865 · Cited by 27
The impact of antidiabetic treatment on human hypothalamic infundibular neurons and microglia
Kalsbeek, M. J. T., Wolff, S. E. C., Korpel, N. L., la Fleur, S. E., Romijn, J. A., Fliers, E., Kalsbeek, A., Swaab, D. F., Huitinga, I., Hol, E. M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133868 · Cited by 24
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
Mancinelli, C. R., Rossi, N. D., & Capra, R. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s282390 · Cited by 28
Monocytes in central nervous system remyelination
Forbes, L. H., & Miron, V. E. (2021) · Glia · doi:10.1002/glia.24111 · Cited by 24
Allegretta, C., D’Amico, E., Manuti, V., Avolio, C., & Conese, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073829 · Cited by 27
T cell–neuron interaction in inflammatory and progressive multiple sclerosis biology
Brummer, T., Zipp, F., & Bittner, S. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102588 · Cited by 24
Pagani, F., Testi, C., Grimaldi, A., Corsi, G., Cortese, B., Basilico, B., Baiocco, P., Panfilis, S. D., Ragozzino, D., & Angelantonio, S. D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.10.041 · Cited by 25
Nakajima, A., Yanagimura, F., Saji, E., Shimizu, H., Toyoshima, Y., Yanagawa, K., Arakawa, M., Hokari, M., Yokoseki, A., Wakasugi, T., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02725-x · Cited by 28
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
Sabatino, J. J., Cree, B., & Hauser, S. L. (2025) · Annals of Neurology · doi:10.1002/ana.27270 · Cited by 27
Mason, H. D., Johnson, A. M., Mihelson, N., Mastorakos, P., & McGavern, D. B. (2021) · JCI Insight · doi:10.1172/jci.insight.149229 · Cited by 23
The Role of Microglial Purinergic Receptors in Pain Signaling
Tozaki‐Saitoh, H., Takeda, H., & Inoue, K. (2022) · Molecules · doi:10.3390/molecules27061919 · Cited by 25
Taddei, R. N., Sanchez-Mico, M. V., Bonnar, O., Connors, T. R., Gaona, A., Denbow, D., Frosch, M. P., & Gómez‐Isla, T. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01370-3 · Cited by 23
Wiggermann, V., Endmayr, V., Hernández‐Torres, E., Höftberger, R., Kasprian, G. J., Hametner, S., & Rauscher, A. (2023) · Brain Pathology · doi:10.1111/bpa.13150 · Cited by 22
Self-citationZong, B., Yu, F., Zhang, X., Zhao, W., Li, S., & Li, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260663 · Cited by 24
Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Liu, L., Ma, D., Zhuo, L., Pang, X., You, J., & Feng, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200606231723 · Cited by 21
Hsueh, S., Luo, W., Tweedie, D., Kim, D. S., Kim, Y. K., Hwang, I., Gil, J.-E., Han, B., Chiang, Y. H., Selman, W. R., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00042 · Cited by 22
Standiford, M. M., Grund, E. M., & Howe, C. L. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02360-3 · Cited by 23
Role of DAMPs and cell death in autoimmune diseases: the example of multiple sclerosis
Land, W. G. (2023) · Genes and Immunity · doi:10.1038/s41435-023-00198-8 · Cited by 23
Song, S., Peng, K., Meng, X., Shan, X.-S., Chen, Q., Zhao, W., Shen, B., Qiu, H., Liu, H., Liu, H., et al. (2023) · Anesthesiology · doi:10.1097/aln.0000000000004522 · Cited by 21
Evans, R., Watkins, L. M., Hawkins, K., Santiago, G., Demetriou, C., Naughton, M., Dittmer, M., Rees, M. I., Fitzgerald, D. C., Morgan, B. P., et al. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1094106 · Cited by 22
Temmerman, J., Engelborghs, S., Bjerke, M., & D’haeseleer, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162340 · Cited by 23
Veroni, C., Serafini, B., Rosicarelli, B., Fagnani, C., Aloisi, F., & Agresti, C. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00190 · Cited by 21
Pollock, N. M., Fernandes, J. P., Woodfield, J., Moussa, E., Hlavay, B., Branton, W. G., Wuest, M., Mohammadzadeh, N., Schmitt, L., Plemel, J. R., et al. (2024) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.10.022 · Cited by 21
Vermersch, P., Airas, L., Berger, T., Deisenhammer, F., Grigoriadis, N., Hartung, H.-P., Magyari, M., Popescu, V., Pozzilli, C., Pugliatti, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1495529 · Cited by 21
de Jong, C. G. H. M., Stancic, M., Pinxterhuis, T. H., van Horssen, J., van Dam, A., Gabius, H., & Baron, W. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly081 · Cited by 21
Jansen, M. I., Broome, S. T., & Castorina, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094788 · Cited by 21
Doroshenko, E. R., Drohomyrecky, P. C., Gower, A., Whetstone, H., Cahill, L. S., Ganguly, M., Spring, S., Yi, T. J., Sled, J. G., & Dunn, S. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.570425 · Cited by 23
Spiteri, A. G., Wishart, C. L., & King, N. J. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600822 · Cited by 31
Glycolytic reprogramming during microglial polarization in neurological diseases
Li, X., Fang, C., Li, Y., Xiong, X., Xu, X., & Gu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648887 · Cited by 23
Microglia depletion as a therapeutic strategy: friend or foe in multiple sclerosis models?
Mancini, V. S. B. W., Pietro, A. A. D., & Pasquini, L. A. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346538 · Cited by 20
miRNAs in Microglia: Important Players in Multiple Sclerosis Pathology
Walsh, A. D., Nguyen, L., & Binder, M. D. (2021) · ASN NEURO · doi:10.1177/1759091420981182 · Cited by 23
Ioannides, Z. A., Csurhes, P. A., Swayne, A., Foubert, P., Aftab, B. T., & Pender, M. P. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211019772 · Cited by 21
Magnetic Resonance Imaging Correlates of Multiple Sclerosis Immunopathological Patterns
Metz, I., Gavrilova, R. H., Weigand, S. D., Frischer, J. M., Popescu, B. F. G., Guo, Y., Gloth, M., Tobin, W. O., Zalewski, N. L., Lassmann, H., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26163 · Cited by 21
Self-citationZiliotto, N., Bernardi, F., Jakimovski, D., Baroni, M., Bergsland, N., Ramasamy, D. P., Weinstock‐Guttman, B., Zamboni, P., Marchetti, G., Zivadinov, R., et al. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.07.009 · Cited by 20
Microglia regulate cortical remyelination via TNFR1-dependent phenotypic polarization
Boutou, A., Roufagalas, I., Politopoulou, K., Tastsoglou, S., Abouzeid, M., Skoufos, G., de Juan, L. V., Ko, J. H., Kyrargyri, V., Hatzigeorgiou, A. G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114894 · Cited by 22
Self-citationShirahama, S., Okunuki, Y., Lee, M. Y., Karg, M. M., Refaian, N., Krasniqi, D., Connor, K. M., Gregory-Ksander, M. S., & Ksander, B. R. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103417 · Cited by 22
MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis
Asl, E. R., Hosseini, S. E., Tahmasebi, F., Bolandi, N., & Barati, S. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01578-6 · Cited by 19
Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration
Li, Y., Li, Z., Zheng, P., Guan, S., Li, Y., Yao, N., Qi, Z., Zhang, X., Su, L., Jing, J., et al. (2025) · Science · doi:10.1126/science.adq1177 · Cited by 20
Innate immune memory: The evolving role of macrophages in therapy
Damani‐Yokota, P., & Khanna, K. M. (2025) · eLife · doi:10.7554/elife.108276 · Cited by 22
Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation
Abramson, E., Hardman, C., Shimizu, A., Hwang, S. A., Hester, L. D., Snyder, S. H., Wender, P. A., Kim, P. M., & Kornberg, M. D. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.015 · Cited by 18
Borggrewe, M., Kooistra, S. M., Wesseling, E. M., Gierschek, F. L., Brummer, M. L., Nowak, E. C., Medeiros-Furquim, T., Otto, T. A., Lee, S. W., Noelle, R. J., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01186-7 · Cited by 20
Macrophage-Associated Disorders: Pathophysiology, Treatment Challenges, and Possible Solutions
Yadav, D. K., Pradhan, M., Singh, D., & Singh, M. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_4 · Cited by 20
Álvarez‐Sánchez, N., & Dunn, S. E. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_324 · Cited by 21
Animal models and human tissue compared to better understand and treat the epilepsies
Milior, G., Morin‐Brureau, M., Pallud, J., Miles, R., & Huberfeld, G. (2023) · Epilepsia · doi:10.1111/epi.17552 · Cited by 20
BMP7 alleviates trigeminal neuralgia by reducing oligodendrocyte apoptosis and demyelination
Chen, K., Wei, X., Wang, R., Yang, L. C., Zou, D., & Wang, Y. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01681-3 · Cited by 19
Microglia in pediatric brain tumors: The missing link to successful immunotherapy
du Chatinier, A., Velilla, I. Q., Meel, M. H., Hoving, E. W., Hulleman, E., & Metselaar, D. S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101246 · Cited by 22
Perivascular tissue resident memory T cells as therapeutic target in multiple sclerosis
Smolders, J., Fransen, N. L., Hsiao, C., Hamann, J., & Huitinga, I. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1776609 · Cited by 22
Hayashida, S., Masaki, K., Suzuki, S. O., Yamasaki, R., Watanabe, M., Koyama, S., Isobe, N., Matsushita, T., Takahashi, K., Tabira, T., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12898 · Cited by 19
Deciphering the heterogeneity of myeloid cells during neuroinflammation in the single‐cell era
Borst, K., & Prinz, M. (2020) · Brain Pathology · doi:10.1111/bpa.12910 · Cited by 17
Implications of immunometabolism for smouldering MS pathology and therapy
Bittner, S., Pape, K., Klotz, L., & Zipp, F. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00839-6 · Cited by 19
Immunopathology of the optic nerve in multiple sclerosis
Blanco, L. F., Marzin, M. C., Leistra, A., van der Valk, P., Nutma, E., & Amor, S. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac063 · Cited by 19
Neuro-immune crosstalk in depressive symptoms of multiple sclerosis
Wang, C., Zhou, Y., & Feinstein, A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106005 · Cited by 20
Phenomic Microglia Diversity as a Druggable Target in the Hippocampus in Neurodegenerative Diseases
Lana, D., Magni, G., Landucci, E., Wenk, G. L., Pellegrini-Giampietro, D. E., & Giovannini, M. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813668 · Cited by 20
Funk, K. E., Arutyunov, A., Desai, P., White, J. P., Soung, A., Rosen, S. F., Diamond, M., & Klein, R. S. (2021) · Aging Cell · doi:10.1111/acel.13412 · Cited by 16
The Neuroimmunology of Multiple Sclerosis: Fictions and Facts
Pachner, A. R. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.796378 · Cited by 19
González, G. M., Hart, B. A. ‘., Bugiani, M., Plemel, J. R., Schenk, G. J., Kooij, G., & Luchicchi, A. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02923-1 · Cited by 20
Tau overexpression exacerbates neuropathology after repeated mild head impacts in male mice
Cheng, H., Deaton, L. M., Qiu, M., Ha, S., Pacoma, R., Lao, J., Tolley, V., Moran, R., Keeton, A., Lamb, J. R., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104683 · Cited by 16
Shen, J., Yang, B., Xie, Z., Wu, H., Zheng, Z., Wang, J., Wang, P., Zhang, P., Li, W., Ye, Z., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.639527 · Cited by 15
Mendiola, A. S., Church, K. A., Cardona, S. M., Vanegas, D., Garcia, S. A., Macklin, W. B., Lira, S. A., Ransohoff, R. M., Kokovay, E., Lin, C. A., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15616 · Cited by 15
An overview on microglial origin, distribution, and phenotype in Alzheimer's disease
Islam, R., Choudhary, H. H., Rajan, R. G., Vrionis, F. D., & Hanafy, K. A. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30829 · Cited by 18
Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study
Pitombeira, M. S., Koole, M. J. B., Campanholo, K. R., de Souza, A. B. P., Duran, F., Solla, D. J. F., Mendes, M. F., Apóstolos‐Pereira, S. L., Rimkus, C. D. M., Busatto, G. F., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05899-2 · Cited by 20
Guo, X., Liu, Y., Morgan, D., & Zhao, L. (2020) · Aging and Disease · doi:10.14336/ad.2020.0201 · Cited by 16
Impact of dietary polyphenols on neuroinflammation-associated disorders
Revi, N., & Rengan, A. K. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05303-1 · Cited by 17
Xu, L., Yang, S., Zhou, L., Chu, Y., Pang, X., You, Y., Zhang, H., Zhang, L., Zhu, L., Chen, L., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03187-4 · Cited by 20
Han, J., Zhu, K., Zhou, K., Hakim, R., Sankavaram, S. R., Blomgren, K., Lund, H., Zhang, X., & Harris, R. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186824 · Cited by 16
Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes
Shields, C. B., Cai, J., Chu, T., Shields, L. B. E., Zeng, W., Zhang, Y., Wang, Y., & Barnes, G. N. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.300975 · Cited by 21
Tavares-Gomes, L., Monney, C., Neuhaus, G., Francisco, D. M. F., Solis, D., Summerfield, A., Erny, D., Jagannathan, V., & Oevermann, A. (2021) · Glia · doi:10.1002/glia.24002 · Cited by 17
Moog, T. M., McCreary, M., Wilson, A., Stanley, T., Yu, F. F., Pinho, M. C., Guo, X., & Okuda, D. T. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11089-9 · Cited by 17
Jackson, I. M., Buccino, P. J., Azevedo, E. C., Carlson, M. L., Luo, A., Deal, E. M., Kalita, M., Reyes, S. T., Shao, X., Beinat, C., et al. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.05.001 · Cited by 17
Muramyl Dipeptide Administration Delays Alzheimer’s Disease Physiopathology via NOD2 Receptors
Piec, P.-A., Pons, V., Préfontaine, P., & Rivest, S. (2022) · Cells · doi:10.3390/cells11142241 · Cited by 16
G protein-coupled P2Y12 receptor is involved in the progression of neuropathic pain
Ming, L.-G., Hu, D.-X., Zuo, C., & Zhang, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114713 · Cited by 17
Microglia subtypes in acute, subacute, and chronic multiple sclerosis
Prineas, J. W., & Lee, S. (2023) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlad046 · Cited by 16
Sun, C., Shen, Y., Liu, P., Shen, Y., Hu, Y., Li, P., Zhang, Y., Miao, F., & Zhang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713265 · Cited by 16
Kessler, W., Thomas, C., & Kuhlmann, T. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02645-2 · Cited by 17
Quarta, A., Berneman, Z. N., & Ponsaerts, P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru0820-536r · Cited by 17
Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis
Vainchtein, I. D., Alsema, A. M., Dubbelaar, M. L., Grit, C., Vinet, J., van Weering, H. R. J., Al‐Izki, S., Biagini, G., Brouwer, N., Amor, S., et al. (2022) · Glia · doi:10.1002/glia.24297 · Cited by 13
Nheu, D., Ellen, O., Ye, S., Öztürk, E., Pagnin, M., Kertadjaja, S., Theotokis, P., Grigoriadis, N., McLean, C., & Petratos, S. (2022) · Cells · doi:10.3390/cells11233768 · Cited by 16
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Molecular Brain · doi:10.1186/s13041-023-01047-5 · Cited by 16
Nicholas, R. S., Magliozzi, R., Marastoni, D., Howell, O. W., Roncaroli, F., Muraro, P. A., Reynolds, R., & Friede, T. (2023) · Annals of Neurology · doi:10.1002/ana.26870 · Cited by 15
Hwang, D. H., Boehm, A., Rostami, A. M., Zhang, G., & Ćirić, B. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577778 · Cited by 15
Periventricular magnetisation transfer abnormalities in early multiple sclerosis
Pirpamer, L., Kincses, B., Kincses, Z. T., Kiss, C., Damulina, A., Khalil, M., Stollberger, R., Schmidt, R., Enzinger, C., & Ropele, S. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103012 · Cited by 15
Sahara, N., Maeda, J., Ishikawa, A., Tokunaga, M., Suhara, T., & Higuchi, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179933 · Cited by 16
Mancini, V. S. B. W., Pietro, A. A. D., de Olmos, S., Pinto, P. S., Vence, M., Marder, M., Igaz, L. M., Marcora, M. S., Pasquini, J. M., Correale, J. D., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15566 · Cited by 16
Fransson, J., Bachelin, C., Deknuydt, F., Ichou, F., Guillot‐Noël, L., Ponnaiah, M., Gloaguen, A., Maillart, É., Stankoff, B., Tenenhaus, A., et al. (2024) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200312 · Cited by 17
Brain organoid methodologies to explore mechanisms of disease in progressive multiple sclerosis
Simões-Abade, M. B. C., Patterer, M., Nicaise, A. M., & Pluchino, S. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1488691 · Cited by 14
Rayatpour, A., & Javan, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105441 · Cited by 14
Alves‐Leon, S. V., Ferreira, C. D. S., Herlinger, A. L., Fontes-Dantas, F. L., Lopes, F. C. R., Francisco, R. D. S., Gonçalves, J. P. D. C., de Araújo, A. D., Rêgo, C. C. D. S., Higa, L. M., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.639364 · Cited by 14
Loss of Homeostatic Microglia Signature in Prion Diseases
Wang, Y., Hartmann, K., Thies, E., Mohammadi, B., Altmeppen, H., Sepulveda-Falla, D., Glatzel, M., & Krasemann, S. (2022) · Cells · doi:10.3390/cells11192948 · Cited by 12
The proteomic landscape of microglia in health and disease
Davis, E., & Lloyd, A. F. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1379717 · Cited by 13
Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology
Fan, H., Fu, Q., Du, G., Ling, Q., Shi, X., Wang, D., & Yang, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70135 · Cited by 13
Gharibani, P. M., Abramson, E., Shanmukha, S., Smith, M. D., Godfrey, W. H., Lee, J. J., Hu, J., Baydyuk, M., Dorion, M., Deng, X., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3434 · Cited by 15
van Wageningen, T. A., Antonovaité, N., Paardekam, E. J., Brevé, J. J. P., Iannuzzi, D., & van Dam, A. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02134-x · Cited by 12
Local and remote interactions between macrophages and microglia in neurological conditions
Boillée, S. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.11.006 · Cited by 14
Yates, R. L., Pansieri, J., Li, Q., Bell, J. S., Yee, S. A., Palace, J. A., Esiri, M. M., & DeLuca, G. C. (2021) · Brain Pathology · doi:10.1111/bpa.13041 · Cited by 14
Microglia from patients with multiple sclerosis display a cell-autonomous immune activation statePreprint
Hyvärinen, T., Lotila, J., Giudice, L., Tujula, I., Nylund, M., Ohtonen, S., Scoyni, F., Jäntti, H., Pihlava, S., Skottman, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.10.627477 · Cited by 14
Nishimura, Y., Masaki, K., Matsuse, D., Yamaguchi, H., Tanaka, T., Matsuo, E., Hayashida, S., Watanabe, M., Matsushita, T., Sadashima, S., et al. (2022) · Brain Pathology · doi:10.1111/bpa.13131 · Cited by 12
Cuní‐López, C., Stewart, R., White, A. R., & Quek, H. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578017 · Cited by 9
Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals
Laaksonen, S., Saraste, M., Nylund, M., Hinz, R., Snellman, A., Rinne, J., Matilainen, M., & Airas, L. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1352116 · Cited by 15
Metadata
- Authors
- Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H.
- Affiliations
- Medical University of Vienna (AT)
- Brigham and Women's Hospital (US)
- Corresponding author
- Lassmann, Hans
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-05-24
- Volume
- 140
- Issue
- 7
- Pages
- 1900-1913
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6057548
- OpenAlex
- W2620266814
- Cited by
- 684
- References
- 68
- Citations by year
- 2026: 62 · 2025: 65 · 2024: 78 · 2023: 87 · 2022: 92 · 2021: 116 · 2020: 71 · 2019: 60 · 2018: 43 · 2017: 10
- FWCI
- 39.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- NIH (R01NS088137)
- National Multiple Sclerosis Society (5092A1)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- multiple sclerosis, microglia, macrophages, homeostatic microglia, microglial activation, P2Y12 receptor, TMEM119, normal-appearing white matter, demyelination, neurodegeneration, lesion activity, disease duration, pro-inflammatory phenotype, anti-inflammatory phenotype, phagocytosis, oxidative damage, antigen presentation, T cell costimulation, microglial origin
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aging, Demyelinating Diseases, Female, Homeostasis, Humans, Macrophage Activation, Male, Membrane Proteins, Middle Aged, Multiple Sclerosis, Nerve Degeneration, Case-Control Studies, Microglia, Receptors, Purinergic P2Y12, White Matter
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
